APO Research
Talk to an analyst

APO RESEARCH · REPORT

Glucagon-like Peptide-2 (GLP-2) Agonist

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Analysis and Forecast 2026-2032

2 January 2026193 pages

Choose your research edition.

Industry ResearchGlucagon-like Peptide-2 (GLP-2) Agonist Industry Research Report 2026106 pages · $2,950 USDIndustry Growth & TrendsGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Industry Growth and Trends Forecast to 203270 pages · $3,450 USDMarket StructureGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032179 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Glucagon-like Peptide-2 (GLP-2) Agonist Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Glucagon-like Peptide-2 (GLP-2) Agonist market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Glucagon-like Peptide-2 (GLP-2) Agonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Glucagon-like Peptide-2 (GLP-2) Agonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Glucagon-like Peptide-2 (GLP-2) Agonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Glucagon-like Peptide-2 (GLP-2) Agonist is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Glucagon-like Peptide-2 (GLP-2) Agonist include Takeda Pharmaceuticals. etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Glucagon-like Peptide-2 (GLP-2) Agonist, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Glucagon-like Peptide-2 (GLP-2) Agonist, also provides the sales of main regions and countries. Of the upcoming market potential for Glucagon-like Peptide-2 (GLP-2) Agonist, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Glucagon-like Peptide-2 (GLP-2) Agonist sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Glucagon-like Peptide-2 (GLP-2) Agonist market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Glucagon-like Peptide-2 (GLP-2) Agonist sales, projected growth trends, production technology, application and end-user industry.

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Company

Takeda Pharmaceuticals

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Type

Gattex

Revestive

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Application

Hospital

Pharmacy

Other

Glucagon-like Peptide-2 (GLP-2) Agonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glucagon-like Peptide-2 (GLP-2) Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glucagon-like Peptide-2 (GLP-2) Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glucagon-like Peptide-2 (GLP-2) Agonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Glucagon-like Peptide-2 (GLP-2) Agonist in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Glucagon-like Peptide-2 (GLP-2) Agonist manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Glucagon-like Peptide-2 (GLP-2) Agonist sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Gattex Major Manufacturers Table 3. Revestive Major Manufacturers Table 4. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Pharmacy Major Manufacturers Table 7. Other Major Manufacturers Table 8. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends Table 9. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Drivers Table 10. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Opportunities and Challenges Table 11. Glucagon-like Peptide-2 (GLP-2) Agonist Industry Restraints Table 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2021-2026) Table 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2027-2032) Table 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2021-2026) & (K Units) Table 19. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2027-2032) & (K Units) Table 20. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2021-2026) Table 21. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2027-2032) Table 22. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Manufacturers (2021-2026) Table 26. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Glucagon-like Peptide-2 (GLP-2) Agonist Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Glucagon-like Peptide-2 (GLP-2) Agonist Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers, Product Type & Application Table 30. Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Glucagon-like Peptide-2 (GLP-2) Agonist by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2021-2026) Table 37. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2027-2032) Table 38. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 40. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2027-2032) & (K Units) Table 41. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2021-2026) Table 42. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2027-2032) Table 43. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2021-2026) & (US$/Unit) Table 44. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2027-2032) & (US$/Unit) Table 45. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2021-2026) Table 49. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2027-2032) Table 50. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 52. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2027-2032) & (K Units) Table 53. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2021-2026) Table 54. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2027-2032) Table 55. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2021-2026) & (US$/Unit) Table 56. Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2027-2032) & (US$/Unit) Table 57. Takeda Pharmaceuticals Company Information Table 58. Takeda Pharmaceuticals Business Overview Table 59. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolio Table 61. Takeda Pharmaceuticals Recent Development Table 62. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2026) & (US$ Million) Table 63. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2027-2032) & (US$ Million) Table 64. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 65. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2027-2032) & (K Units) Table 66. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Type (2021-2026) & (US$/Unit) Table 67. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Type (2027-2032) & (US$/Unit) Table 68. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2026) & (US$ Million) Table 69. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2027-2032) & (US$ Million) Table 70. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 71. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2027-2032) & (K Units) Table 72. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Application (2021-2026) & (US$/Unit) Table 73. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Application (2027-2032) & (US$/Unit) Table 74. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 75. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 76. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 77. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 78. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 79. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 80. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Country (2021-2026) & (US$/Unit) Table 81. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Country (2027-2032) & (US$/Unit) Table 82. United States Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 83. Canada Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 84. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2026) & (US$ Million) Table 85. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2027-2032) & (US$ Million) Table 86. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 87. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2027-2032) & (K Units) Table 88. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Type (2021-2026) & (US$/Unit) Table 89. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Type (2027-2032) & (US$/Unit) Table 90. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2026) & (US$ Million) Table 91. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2027-2032) & (US$ Million) Table 92. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 93. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2027-2032) & (K Units) Table 94. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Application (2021-2026) & (US$/Unit) Table 95. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Application (2027-2032) & (US$/Unit) Table 96. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 98. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 99. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 100. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 101. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 102. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Country (2021-2026) & (US$/Unit) Table 103. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Country (2027-2032) & (US$/Unit) Table 104. Germany Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 105. France Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 106. U.K. Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 107. Italy Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 108. Netherlands Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 109. China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2026) & (US$ Million) Table 110. China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2027-2032) & (US$ Million) Table 111. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 112. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2027-2032) & (K Units) Table 113. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Type (2021-2026) & (US$/Unit) Table 114. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Type (2027-2032) & (US$/Unit) Table 115. China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2026) & (US$ Million) Table 116. China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2027-2032) & (US$ Million) Table 117. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 118. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2027-2032) & (K Units) Table 119. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Application (2021-2026) & (US$/Unit) Table 120. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Application (2027-2032) & (US$/Unit) Table 121. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2026) & (US$ Million) Table 122. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2027-2032) & (US$ Million) Table 123. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 124. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2027-2032) & (K Units) Table 125. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Type (2021-2026) & (US$/Unit) Table 126. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Type (2027-2032) & (US$/Unit) Table 127. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2026) & (US$ Million) Table 128. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2027-2032) & (US$ Million) Table 129. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 130. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2027-2032) & (K Units) Table 131. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Application (2021-2026) & (US$/Unit) Table 132. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Application (2027-2032) & (US$/Unit) Table 133. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 135. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 136. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 137. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 138. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 139. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Country (2021-2026) & (US$/Unit) Table 140. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Country (2027-2032) & (US$/Unit) Table 141. Japan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 142. South Korea Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 143. India Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 144. Australia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 145. China Taiwan Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 146. Southeast Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 147. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2026) & (US$ Million) Table 148. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2027-2032) & (US$ Million) Table 149. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2026) & (K Units) Table 150. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2027-2032) & (K Units) Table 151. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Type (2021-2026) & (US$/Unit) Table 152. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Type (2027-2032) & (US$/Unit) Table 153. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2026) & (US$ Million) Table 154. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2027-2032) & (US$ Million) Table 155. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2026) & (K Units) Table 156. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2027-2032) & (K Units) Table 157. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Application (2021-2026) & (US$/Unit) Table 158. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Application (2027-2032) & (US$/Unit) Table 159. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 161. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 162. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 163. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021-2026) & (K Units) Table 164. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2027-2032) & (K Units) Table 165. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Country (2021-2026) & (US$/Unit) Table 166. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Country (2027-2032) & (US$/Unit) Table 167. Brazil Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 168. Argentina Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 169. Chile Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 170. Colombia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 171. Peru Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 172. Saudi Arabia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 173. Israel Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 174. UAE Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 175. Turkey Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 176. Iran Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 177. Egypt Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Table 178. Key Raw Materials Table 179. Raw Materials Key Suppliers Table 180. Glucagon-like Peptide-2 (GLP-2) Agonist Distributors List Table 181. Glucagon-like Peptide-2 (GLP-2) Agonist Customers List Table 182. Research Programs/Design for This Report Table 183. Authors List of This Report Table 184. Secondary Sources Table 185. Primary Sources List of Figures Figure 1. Glucagon-like Peptide-2 (GLP-2) Agonist Image Figure 2. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Share 2021 VS 2025 VS 2032 Figure 4. Gattex Image Figure 5. Revestive Image Figure 6. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Pharmacy Image Figure 10. Other Image Figure 11. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (2021-2032) & (US$ Million) Figure 13. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2021-2032) Figure 16. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales (2021-2032) & (K Units) Figure 17. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Glucagon-like Peptide-2 (GLP-2) Agonist Sales YoY (2021-2032) & (K Units) Figure 20. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales YoY (2021-2032) & (K Units) Figure 21. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Glucagon-like Peptide-2 (GLP-2) Agonist Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Glucagon-like Peptide-2 (GLP-2) Agonist Sales YoY (2021-2032) & (K Units) Figure 24. Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2021-2032) Figure 30. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2021-2032) Figure 33. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2021-2032) Figure 36. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2021-2032) Figure 39. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Type (2021-2032) Figure 40. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Type (2021-2032) Figure 41. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Application (2021-2032) Figure 42. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Application (2021-2032) Figure 43. North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Country (2021-2032) Figure 44. North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Country (2021-2032) Figure 45. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Type (2021-2032) Figure 46. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Type (2021-2032) Figure 47. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Application (2021-2032) Figure 48. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Application (2021-2032) Figure 49. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Country (2021-2032) Figure 50. Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Country (2021-2032) Figure 51. China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Type (2021-2032) Figure 52. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Type (2021-2032) Figure 53. China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Application (2021-2032) Figure 54. China Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Application (2021-2032) Figure 55. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Type (2021-2032) Figure 56. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Type (2021-2032) Figure 57. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Application (2021-2032) Figure 58. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Application (2021-2032) Figure 59. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Country (2021-2032) Figure 60. Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Country (2021-2032) Figure 61. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Type (2021-2032) Figure 62. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Type (2021-2032) Figure 63. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Application (2021-2032) Figure 64. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Application (2021-2032) Figure 65. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Share by Country (2021-2032) Figure 66. SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales Share by Country (2021-2032) Figure 67. Glucagon-like Peptide-2 (GLP-2) Agonist Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Glucagon-like Peptide-2 (GLP-2) Agonist Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Gattex
  • Revestive
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Takeda Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Glucagon-like Peptide-2 (GLP-2) Agonist Market by Type
  3. 1.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Gattex
  5. 1.2.3 Revestive
  6. 1.3 Glucagon-like Peptide-2 (GLP-2) Agonist Market by Application
  7. 1.3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Pharmacy
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Glucagon-like Peptide-2 (GLP-2) Agonist Market Dynamics
  1. 2.1 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Trends
  2. 2.2 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Drivers
  3. 2.3 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Opportunities and Challenges
  4. 2.4 Glucagon-like Peptide-2 (GLP-2) Agonist Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region
  3. 3.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2021-2026)
  5. 3.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Region (2027-2032)
  6. 3.2.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region
  9. 3.4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2021-2026)
  11. 3.4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Region (2027-2032)
  12. 3.4.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Manufacturers
  2. 4.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Manufacturers
  6. 4.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Glucagon-like Peptide-2 (GLP-2) Agonist Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Glucagon-like Peptide-2 (GLP-2) Agonist Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers, Product Type & Application
  13. 4.7 Global Glucagon-like Peptide-2 (GLP-2) Agonist Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Market CR5 and HHI
  16. 4.8.2 2025 Glucagon-like Peptide-2 (GLP-2) Agonist Tier 1, Tier 2, and Tier 3
5 Glucagon-like Peptide-2 (GLP-2) Agonist Market by Type
  1. 5.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type
  2. 5.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type
  6. 5.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Type (2021-2032)
  9. 5.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type
6 Glucagon-like Peptide-2 (GLP-2) Agonist Market by Application
  1. 6.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application
  2. 6.1.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application
  6. 6.2.1 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Sales Market Share by Application (2021-2032)
  9. 6.3 Global Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application
7 Company Profiles
  1. 7.1 Takeda Pharmaceuticals
  2. 7.1.1 Takeda Pharmaceuticals Company Information
  3. 7.1.2 Takeda Pharmaceuticals Business Overview
  4. 7.1.3 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceuticals Glucagon-like Peptide-2 (GLP-2) Agonist Product Portfolio
  6. 7.1.5 Takeda Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Type
  2. 8.1.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2032)
  3. 8.1.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2032)
  4. 8.1.3 North America Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2021-2032)
  5. 8.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Application
  6. 8.2.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2032)
  7. 8.2.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2032)
  8. 8.2.3 North America Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2021-2032)
  9. 8.3 North America Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
  10. 8.3.1 North America Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Glucagon-like Peptide-2 (GLP-2) Agonist Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Type
  2. 9.1.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2032)
  3. 9.1.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2032)
  4. 9.1.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2021-2032)
  5. 9.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Application
  6. 9.2.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2032)
  7. 9.2.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2032)
  8. 9.2.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2021-2032)
  9. 9.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
  10. 9.3.1 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Glucagon-like Peptide-2 (GLP-2) Agonist Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Type
  2. 10.1.1 China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2032)
  3. 10.1.2 China Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2032)
  4. 10.1.3 China Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2021-2032)
  5. 10.2 China Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Application
  6. 10.2.1 China Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2032)
  7. 10.2.2 China Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2032)
  8. 10.2.3 China Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Type
  2. 11.1.1 Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2032)
  3. 11.1.2 Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2032)
  4. 11.1.3 Asia Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2021-2032)
  5. 11.2 Asia Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Application
  6. 11.2.1 Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2032)
  7. 11.2.2 Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2032)
  8. 11.2.3 Asia Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2021-2032)
  9. 11.3 Asia Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
  10. 11.3.1 Asia Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Glucagon-like Peptide-2 (GLP-2) Agonist Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Type
  2. 12.1.1 SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Price by Type (2021-2032)
  5. 12.2 SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Application
  6. 12.2.1 SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Price by Application (2021-2032)
  9. 12.3 SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Market Size by Country
  10. 12.3.1 SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Glucagon-like Peptide-2 (GLP-2) Agonist Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Glucagon-like Peptide-2 (GLP-2) Agonist Value Chain Analysis
  2. 13.1.1 Glucagon-like Peptide-2 (GLP-2) Agonist Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Glucagon-like Peptide-2 (GLP-2) Agonist Production Mode & Process
  6. 13.2 Glucagon-like Peptide-2 (GLP-2) Agonist Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Glucagon-like Peptide-2 (GLP-2) Agonist Distributors
  9. 13.2.3 Glucagon-like Peptide-2 (GLP-2) Agonist Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst